DENA ROBIN: Open Payments
NPI 1255739959 · LAFAYETTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$845 in 55 payments from 16 companies in 2025. Trend: 2023 $473 · 2024 $658 · 2025 $845
Food & beverage: $845
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 23 | $260 |
| Madrigal Pharmaceuticals | 5 | $83 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $79 |
| Janssen Biotech, Inc. | 4 | $70 |
| Ipsen Biopharmaceuticals, Inc | 3 | $55 |
| Ardelyx, Inc. | 2 | $51 |
| Phathom Pharmaceuticals, Inc. | 4 | $48 |
| Novo Nordisk Inc | 2 | $38 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $30 |
| VIVUS LLC | 1 | $25 |
Products named: RINVOQ, SKYRIZI, REZDIFFRA, TREMFYA, ENTYVIO, CREON, IQIRVO, IBSRELA.
Industry payments across LA — which companies pay providers there.
